December 11, 2009 (FinancialWire) — Vivakor, Inc. (OTCBB: VIVK) said it has entered into an exclusive, $5 million license agreement with consumer product firm Regeneca International, Inc.

The agreement exclusively licenses to Regeneca distribution rights to a new nutraceutical formulation developed by Vivakor and provides for the development of future formulations by Vivakor for Regeneca.

Under the terms of the agreement, Regeneca will be the exclusive worldwide direct-to-consumer distributor for the current formulation as well as any future nutraceutical formulations offered to Regeneca by Vivakor.

Regeneca has committed to purchase from Vivakor a minimum of $5 million in product over the next three years and Vivakor will receive a 15% ownership interest in Regeneca’s outstanding common stock and will be the exclusive supplier of the licensed product to Regeneca.

The companies entered into this agreement following a test marketing of one of Vivakor’s formulations, which was followed by an initial Regeneca order of over $100,000 of product.

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds including nutraceutical products.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.